NASDAQ:APLT Applied Therapeutics Q4 2024 Earnings Report $0.10 0.00 (0.00%) As of 06/1/2026 ProfileEarnings HistoryForecast Applied Therapeutics EPS ResultsActual EPS-$0.24Consensus EPS -$0.18Beat/MissMissed by -$0.06One Year Ago EPSN/AApplied Therapeutics Revenue ResultsActual Revenue$0.00 millionExpected Revenue$0.61 millionBeat/MissMissed by -$615.00 thousandYoY Revenue GrowthN/AApplied Therapeutics Announcement DetailsQuarterQ4 2024Date4/14/2025TimeBefore Market OpensConference Call DateMonday, April 14, 2025Conference Call Time9:30AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Applied Therapeutics Earnings HeadlinesHead-To-Head Survey: Genprex (NASDAQ:GNPX) versus Applied Therapeutics (NASDAQ:APLT)May 31 at 4:13 AM | americanbankingnews.comCycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsFebruary 3, 2026 | businesswire.com"You'll own nothing and be happy" (it's not a theory anymore)On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.June 2 at 1:00 AM | Decentralized Masters (Ad)Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 30, 2026 | businesswire.comApplied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration ExtensionJanuary 29, 2026 | globenewswire.comCycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 29, 2026 | businesswire.comSee More Applied Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email. Email Address About Applied TherapeuticsApplied Therapeutics (NASDAQ:APLT), Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation. The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations. Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.View Applied Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to WaitBraze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameMarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in Results Upcoming Earnings Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
